Octreotide
|
|
|
- CAS-Nr.
- 79517-01-4
- Englisch Name:
- Octreotide
- Synonyma:
- SANDOSTATIN;(D-Phe)-Cys-Phe-(D-Trp)-Lys-Thr-Cys-Thr-ol (Disulfide bond 2-7);Ktreotide;OCTREOTIDE;SMS-201-995;SMS 201-995ac;Octreotide/OTC;Sandostatin LAR;Octreotide xAcetate;r*))-(racetate(salt)
- CBNumber:
- CB0279552
- Summenformel:
- C51H70N10O12S2
- Molgewicht:
- 1079.3
- MOL-Datei:
- 79517-01-4.mol
|
Octreotide Eigenschaften
- Schmelzpunkt:
- 153-156°C
- alpha
- D20 -42° (c = 0.5 in 95% acetic acid)
- storage temp.
- Inert atmosphere,Store in freezer, under -20°C
- Löslichkeit
- H2O: soluble
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
- Stabilität:
- Hygroscopic
- InChIKey
- XQEJFZYLWPSJOV-XJQYZYIXSA-N
- CAS Datenbank
- 79517-01-4
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| WGK Germany |
3 |
|
|
| HS Code |
2937190000 |
|
|
| Toxizität |
TDLo scu-man: 2587 mg/kg:GIT,LVR LANCAO348,1668,1996 |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
|
| Sicherheit |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
Octreotide Chemische Eigenschaften,Einsatz,Produktion Methoden
Chemische Eigenschaften
Colourless to off-white lyophilised solid
Verwenden
Octreotide acetate USP (Sandostatin) is used to treat Mestastatic carcinoid tumors; vasoactive intestinal peptide-secretory tumors.
Indications
Octreotide (Sandostatin) is a synthetic somatostatin
analogue. It is used in a variety of situations and must be
given subcutaneously or intravenously. Most commonly,
it is used as a continuous intravenous infusion in patients
hospitalized with bleeding varices, because it decreases
splanchnic circulation and therefore reduces
portal pressures.A long-acting depot form is approved
for the suppression of severe diarrhea and flushing associated
with malignant carcinoid syndrome and for the
treatment of the profuse watery diarrhea associated
with vasoactive intestinal peptide tumor.
Allgemeine Beschreibung
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
Sicherheitsprofil
A poison by subcutaneous andintravenous routes. Human systemic effects: changes instructure or function of endocrine pancreas, liver functiontests impaired. When heated to decomposition it emitstoxic vapors of NOx and SOx
Octreotide Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Octreotide Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 302)Lieferanten
79517-01-4()Verwandte Suche:
- SMS-201-995
- [r-(r*,r*)]-d-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-threonyl-n-[2-hydroxy-1-(hydroxy-methyl)propyl]-cysteinamide cyclic(2->7)-disulfide
- OCTREOTIDE
- OCTREOTIDE (SMS 201-995), ACETATE
- cyclic(2-7)-disulfide,(r-l-threonyl-n-(2-hydroxy-1-(hydroxymethyl)propyl)
- Octreotide
(D-Phe5,Cys6·11,D-Trp8,L-Threoninol12)-SoMatostatin-14 (5-12), SMS-201-995
- D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxyMethyl)propyl]-
- D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Threoninol (Disulfide bridge Cys2-Cys7)
- (D-Phe5,Cys6·11,D-Trp8,L-Threoninol12)-SoMatostatin-14 (5-12), SMS 201-995
- Octreotide, (D-Phe5,Cys611,D-Trp8,L-Threoninol12)- Somatostatin-14 (5-12)
- (D-PHE5,CYS6,11,D-TRP8,L-THREONINOL12)-SOMATOSTATIN-14 (5-12)
- D-PHE-CYS-PHE-D-TRP-LYS-THR-CYS-THR-ALCOHOL
- D-PHE-CYS-PHE-D-TRP-LYS-THR-CYS-THREONINOL
- DPHE-CYS-PHE-DTRP-LYS-THR-CYS-THR-OL
- D-PHE-CYS-PHE-D-TRP-LYS-THR-CYS-THR-OL [DISULFIDE BRIDGE: CYS2-CYS7]
- FCFWKTCT-OL (DISULFIDE BRIDGE: 2-7)
- H-D-PHE-CYS-PHE-D-TRP-LYS-THR-CYS-L-THREONINOL
- H-D-PHE-CYS-PHE-D-TRP-LYS-THR-CYS-L-THREONINOL, (DISULFIDE BOND)
- H-D-PHE-CYS-PHE-D-TRP-LYS-THR-CYS-THR-OL (DISULFIDE BRIDGE: 2-7)
- d-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-cysteinamid
- r*))-(racetate(salt)
- L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2-7)-disulfide, acetate (salt)
- Sandostatin LAR
- SMS 201-995ac
- D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide Cyclic (2-7)-Disulfide Acetate
- Octreotide (SMS 201-995)
- M.W. 1019.24 C49H66N10O10S2
- acetic acid,10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
- 79517-01-4Octreotide Acetate
- Octreotide acetate,SMS 201995, >99%
- Octreotide acetate (Synonyms: SMS 201-995 (acetate))
- Octreotide xAcetate
- Octreotide acetate (SMS 201-995 (acetate))
- SMS 201-995 (acetate)
- Octreotide acetate，SMS 201995
- Octreotide Acetate (4.37 mg)
- Octreotide?Acetate impurity
- Octreotide acetate salt
- Octreotide USP/EP/BP
- Octreotide Acetate (COLD SHIPMENT REQUIRED) (1477604)
- SANDOSTATIN
- (D-Phe)-Cys-Phe-(D-Trp)-Lys-Thr-Cys-Thr-ol (Disulfide bond 2-7)
- Octreotide/OTC
- Ktreotide
- 79517-01-4
- C49H66N10O10S2C2H4O2
- C49H66N10O10S2
- C51H70N10O12S2
- C49H66N10O10S2xCH3COOH
- peptide
- Somatostatin receptor
- Intermediates & Fine Chemicals
- Peptides
- Pharmaceuticals
- Amino Acid Derivatives
